Tirzepatide dosage

Protocol

1. 1

   Reconstitute the vial

   Branded pens (Mounjaro, Zepbound) ship pre-filled and require no reconstitution. Compounded vials typically supply lyophilized 10 to 30 mg powder reconstituted with 1 to 2 mL bacteriostatic water; a 2.5 mg starter dose draws 8 to 25 units on a U100 insulin syringe depending on final concentration.

   Open tool →
2. 2

   Measure the dose

   Typical Tirzepatide dose is 10 mg (Titrated from 2.5 mg weekly up by 2.5 mg every 4 weeks to a target of 5, 10, or 15 mg weekly). Use a weight-based calculator for individual adjustments.

   Open tool →
3. 3

   Set the frequency

   Administer weekly. Half-life of 120 hours anchors the dosing interval.

   Open tool →
4. 4

   Cycle if needed

   Not cycled; titrated up over months and continued indefinitely while clinically appropriate

   Open tool →
5. 5

   Monitor for side effects

   Watch for: nausea; diarrhea; vomiting; constipation. Stop or reduce dose if tolerability breaks down.

Why this dose

Synthetic 39-amino-acid peptide that activates both GIP and GLP-1 receptors. Potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic and brainstem satiety circuits.

The typical dose (10 mg) reflects Titrated from 2.5 mg weekly up by 2.5 mg every 4 weeks to a target of 5, 10, or 15 mg weekly. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

Tirzepatide is administered via the subcutaneous route. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose.

Onset of action runs around 24 hours after administration. Peak effect lands near 3 days post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: ~5 day terminal half-life supports once-weekly SC dosing. Steady state reached after ~4 weeks at a fixed dose.

Cycling and tolerance

Not cycled; titrated up over months and continued indefinitely while clinically appropriate

Effects to expect at typical dose

• Dual GIP plus GLP-1 receptor agonist with a ~5-day half-life supporting once-weekly subcutaneous dosing
• SURMOUNT-1 reported ~22.5% mean body-weight loss at 15 mg over 72 weeks versus 2.4% on placebo
• Lowers HbA1c by ~1.9 to 2.6 percentage points in type 2 diabetes across SURPASS trials
• Outperformed semaglutide 1.0 mg head-to-head on weight loss and HbA1c in SURPASS-2
• GI effects (nausea, diarrhea, vomiting) drive most discontinuations and ease with slow titration
• Lean-mass loss observed in body-composition substudies; resistance training and protein intake mitigate this

Side effects and interactions

Common side effects

• nausea
• diarrhea
• vomiting
• constipation
• decreased appetite

Notable interactions

• insulin (major): additive hypoglycemia risk; insulin dose typically reduced
• sulfonylureas (glipizide, glyburide) (major): hypoglycemia risk, sulfonylurea dose often reduced
• oral medications (general) (moderate): delayed gastric emptying can alter absorption kinetics
• oral contraceptives (moderate): reduced exposure after first dose; backup contraception recommended for 4 weeks after initiation and each dose escalation
• warfarin (moderate): monitor INR due to altered absorption

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Tirzepatide profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

allowed

DEA / Rx

Rx only (not a controlled substance)

Pregnancy

Not recommended; discontinue 2 months before planned pregnancy

Legal status

Prescription only; FDA-approved 2022 (T2DM, Mounjaro) and 2023 (chronic weight management, Zepbound)

Do not use if

• personal or family history of medullary thyroid carcinoma
• multiple endocrine neoplasia type 2
• pregnancy
• history of pancreatitis (use caution)
• severe gastroparesis

Related research